Ecopetrol SA vs Novartis AG — how do they compare? Ecopetrol SA trades at $16 (market cap $30.44B), while Novartis AG trades at $151.12 (market cap $287.66B). The key difference: Novartis AG is far larger — about 9.5× Ecopetrol SA's market cap, and Ecopetrol SA pays the higher dividend (4.06%). Which is the better fit depends on your goals.
| EC | NVS | |
|---|---|---|
Market Cap | $30.44B | $287.66B |
Sector | Energy | Health |
52-Week High | $16.58 | $168.62 |
52-Week Low | $8.29 | $113.50 |
Enterprise Value | $58.23B | $327.68B |
Dividend Yield | 4.06% | 3.14% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novartis (NVS) trades at $150.36, down 1.96% with bearish technical signals. The company maintains strong profitability with 75.38% gross margins and 23.92% net income margin, though recent earnings show mixed results with one beat and two misses. Recent acquisitions including Myricx Bio for up to $1.5 billion expand the oncology pipeline, while regulatory approvals for Itvisma and positive drug trial data support growth prospects.
While analyst consensus leans cautious with 68% hold ratings, Novartis' robust cash flow generation and strategic pipeline investments provide long-term value. Key risks include execution challenges from recent acquisitions and competitive pressures in pharmaceuticals. The stock offers stability through strong fundamentals but faces near-term technical headwinds.
Trailing returns across standard periods
Latest headlines on both assets
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →